Examkin

Question

Difficulty: MediumHemodynamic and Coagulation Processes

A 58-year-old man is brought to the emergency department due to a persistent nosebleed that began 3 hours ago. He has a history of type 2 diabetes mellitus, hypertension, and end-stage renal disease. The patient reports missing his last three hemodialysis sessions due to a lack of transportation. His blood pressure is 168/92 mmHg, and his heart rate is 94/min. Physical examination shows continuous oozing of blood from both nares despite the application of direct pressure and anterior nasal packing. Laboratory studies reveal the following:

Hemoglobin: 9.2 g/dL
Platelet count: 210,000/mm³
Blood urea nitrogen: 96 mg/dL
Serum creatinine: 7.8 mg/dL
Prothrombin time: 11 seconds
Partial thromboplastin time: 26 seconds

Which of the following best describes the mechanism of action of the most appropriate initial pharmacologic therapy for this patient's bleeding?

  1. Stimulation of endothelial cells to release stored von Willebrand factorAnswer
  2. B
    Replenishment of circulating coagulation factors to promote fibrin formation
  3. C
    Provision of functional donor platelets to overcome circulating inhibitors
  4. D
    Competitive inhibition of plasminogen activation to stabilize existing clots
  5. E
    Cleavage of ultra-large von Willebrand factor multimers to restore microcirculation

Answer

The most appropriate initial pharmacologic therapy is desmopressin (DDAVP), which works by stimulating endothelial cells to release stored von Willebrand factor.
The patient is experiencing acute mucosal bleeding due to uremic platelet dysfunction, a consequence of his missed hemodialysis sessions leading to the accumulation of uremic toxins. These toxins interfere with platelet-platelet and platelet-endothelium interactions, specifically impairing von Willebrand factor (vWF) binding and glycoprotein IIb/IIIa function. This results in defective primary hemostasis characterized by a prolonged bleeding time, but a normal platelet count, prothrombin time (PT), and partial thromboplastin time (PTT). The most appropriate initial pharmacologic therapy is desmopressin (DDAVP). DDAVP is a synthetic analogue of vasopressin that stimulates the release of vWF and factor VIII from the Weibel-Palade bodies of endothelial cells. The sudden increase in circulating high-molecular-weight vWF multimers enhances platelet adhesion to the damaged endothelium, effectively arresting the bleeding. While resuming hemodialysis is the definitive treatment to clear the uremic toxins, DDAVP is utilized for rapid, short-term hemostatic control.

Step-by-Step Solution

1
Analyze the patient's clinical presentation and laboratory results.
The patient has mucosal bleeding (epistaxis), elevated BUN and creatinine due to missed dialysis, a normal platelet count, and normal coagulation studies (PT, PTT).
To accurately diagnose the underlying cause of the bleeding.
2
Identify the primary pathophysiologic defect based on the clinical findings.
The findings indicate uremic platelet dysfunction, a qualitative platelet defect caused by the accumulation of uremic toxins (e.g., guanidinosuccinic acid) that impair platelet adhesion and aggregation.
Understanding the precise defect is essential for selecting targeted, effective therapy.
3
Determine the most appropriate initial pharmacologic intervention and its cellular mechanism.
Desmopressin (DDAVP) is the appropriate initial pharmacotherapy. It acts by inducing the exocytosis of von Willebrand factor and factor VIII from endothelial Weibel-Palade bodies, temporarily correcting the adhesion defect.
While resuming hemodialysis is the definitive treatment to clear the toxins, DDAVP provides rapid, short-term hemostasis in acute bleeding scenarios.

Key Concept

Uremic platelet dysfunction causes abnormal primary hemostasis despite a normal platelet count and normal coagulation studies. Desmopressin (DDAVP) is the initial pharmacotherapy of choice, acting by releasing stored von Willebrand factor from endothelial cells to facilitate platelet adhesion.
Rate this question

Topics

Hemodynamic and Coagulation Processes

More questions from this topic